Save 80% of Time and Money on FDA 2253 Submissions
Zinc Ahead has announced a game-changing ability to directly submit post-marketing submissions through the FDA’s electronic submissions gateway, saving clients 80% of the time and money involved in this previously time-consuming process.
The FDA recently announced that from 15 June 2015 they will accept Promotional 2253 submissions in eCTD using the new Module 1 (v3.3). Life Sciences companies will be required to submit all Post-marketing Promotional Materials (Form FDA 2253 Submissions) and Pre-submissions of Promotional Materials for Accelerated Approval Products (subpart H and subpart E) electronically 24 months after their final guidance is issued.
Zinc’s flagship product, Zinc MAPS, offers an end-to-end process which facilitates the review, approval and direct eCTD submission to the FDA gateway in a contained, compliant software solution and will be available on the date that the gateway opens. No other third party integration products are required.
Zinc clients have the option to either directly submit the eCTD Submission package from Zinc MAPS to the FDA ESG or they can choose to have the eCTD Submission package delivered to their desktop or a secure server.
“Zinc continues to monitor the industry and stay ahead of its clients’ needs through continuous innovation in its product solutions,” said Dom Eaton, President of Product & Professional Services at Zinc. “Our latest enhancement to the Zinc MAPS product provides our clients a solution to streamline a submission resulting in reduced time and costs associated with compiling, packaging and shipping submissions to the FDA. Our clients can realize a savings of up to 80% with this solution versus manual submission preparation and physical materials.”
Zinc will enhance this functionality with the release of Zinc MAPS v15 which will convert the 2253 submission package into a validated eCTD format. Other enhancements to the 2253 submission process in Zinc MAPS v15 include the ability to create multiple submissions for jobs containing products from different centers and/or application types, the ability to edit submissions before sending to the FDA, the ability to create submissions of jobs that share a primary or secondary brand, the ability for the 2253 Admin to filter jobs on Brand, Audience and Dissemination Date, and enhancements to the 2253 Admin area.
Dale Cooke, an independent FDA regulatory expert at PhillyCooke Consulting said: “Making eCTD submissions available now shows that Zinc is committed to making the submission of post-marketing promotional materials to the FDA fast and simple. This gives Zinc clients the ability to begin implementing eCTD well ahead of it becoming a requirement and will help companies ensure compliance.” PhillyCooke Consulting helps companies develop compliant communications for FDA-regulated products.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance